The Oncologist current issue

Academia-Pharma Intersect: Providing a Broader Perspective on Drug Development Synergies between Academia and Industry

Chabner, B. A. — Fri, 29 Jan 2010 15:39:25 PST

Histology Matters: Individualizing Treatment in Non-Small Cell Lung Cancer

Neal, J. W. — Fri, 29 Jan 2010 15:39:25 PST

This editorial discusses the West paper published in this issue of The Oncologist on the role of histology in non-small cell lung cancer treatment.

Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective

Fri, 29 Jan 2010 15:39:25 PST

This review presents an overview of the most recent data using the novel agents thalidomide, bortezomib, and lenalidomide in the treatment of multiple myeloma and summarizes European treatment practices incorporating these novel agents.

Therapeutic Usefulness of Postoperative Adjuvant Chemotherapy with Tegafur-Uracil (UFT) in Patients with Breast Cancer: Focus on the Results of Clinical Studies in Japan

Nakayama, T., Noguchi, S. — Fri, 29 Jan 2010 15:39:25 PST

This review provides a brief description of the development of oral fluoropyrimidine chemotherapy regimens and summarizes the results of clinical studies of tegafur plus uracil in breast cancer conducted in Japan, leading to the identification of patients most likely to benefit from treatment with this oral 5-fluorouracil.

Combining Targeted Therapies: Practical Issues to Consider at the Bench and Bedside

Rodon, J., Perez, J., Kurzrock, R. — Fri, 29 Jan 2010 15:39:25 PST

The article reviews the issues that must be considered when combining targeted therapies in early clinical drug development and proposes various novel trial designs that are logical for determining the efficacy of a drug or drug combination for personalized treatment.

Esthesioneuroblastoma (Olfactory Neuroblastoma) with Ectopic ACTH Syndrome: A Multidisciplinary Case Presentation from the Joan Karnell Cancer Center of Pennsylvania Hospital

Mintzer, D. M., Zheng, S., Nagamine, M., Newman, J., Benito, M. — Fri, 29 Jan 2010 15:39:25 PST

The article reports on a case of ectopic adrenocorticotropic hormone production with esthesioneuroblastoma with a review of the literature and management.

Repeated Spontaneous Pregnancies and Successful Deliveries After Repeated Autologous Stem Cell Transplantation and GnRH-Agonist Treatment

Blumenfeld, Z., Zuckerman, T. — Fri, 29 Jan 2010 15:39:25 PST

This article presents a case of repeated spontaneous pregnancies and successful deliveries in a young woman treated with repeated stem cell transplantation and gonadotropin-releasing hormone agonist therapy.

Parathyroid Carcinoma: Current Understanding and New Insights into Gene Expression and Intraoperative Parathyroid Hormone Kinetics

Abdelgadir Adam, M., Untch, B. R., Olson, J. A. — Fri, 29 Jan 2010 15:39:26 PST

This review summarizes the current knowledge on parathyroid carcinoma and describes new information on parathyroid carcinoma gene expression and operative management using intraoperative parathyroid hormone monitoring.

The Evolving Role of Monoclonal Antibodies in Colorectal Cancer: Early Presumptions and Impact on Clinical Trial Development

Eng, C. — Fri, 29 Jan 2010 15:39:26 PST

The article examines the role of molecular markers pertaining to the appropriate use of targeted biologic agents in the treatment of metastatic colorectal cancer and discusses cost-effectiveness issues related to these agents.

Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib

Fri, 29 Jan 2010 15:39:26 PST

This retrospective study explores the potential association between early skin toxicity and efficacy in hepatocellular carcinoma patients treated with sorafenib.

Do We Have Enough Evidence to Implement Particle Therapy as Standard Treatment in Lung Cancer? A Systematic Literature Review

Fri, 29 Jan 2010 15:39:26 PST

This article systematically reviews the currently available evidence on the clinical effectiveness and cost-effectiveness of particle therapy in lung cancer.

FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma

Summers, J., Cohen, M. H., Keegan, P., Pazdur, R. — Fri, 29 Jan 2010 15:39:26 PST

This report describes the clinical trial results that led to the U.S. FDA approval of bevacizumab in combination with interferon for the treatment of renal cell carcinoma.

Immunotherapy of Cancer: Key Findings and Commentary on the Third Tegernsee Conference

Fri, 29 Jan 2010 15:39:26 PST

This report summarizes the key findings of the Third Tegernsee Conference on Immunotherapy of Cancer held recently in Feldafing, Germany.